$TEM Q2 EARNINGS • Revenue $383M vs Est. $380M • EPS ($0.04) vs Est. ($0.15) • EBITDA $8M vs Est. $9M • Diagnostics Revenue: $289M (+20% YoY) FY26 Guidance • Revenue $1.61B vs Est. $1.59B • EBITDA $65M vs Est. $65M Tempus says its Personalis partnership has already proven the value of combining “highly sensitive MRD technology” with its commercial infrastructure.
View on X ↗